TNF Inhibitors Should Carry Class Warnings For Lymphoma, CHF – FDA Cmte.
Executive Summary
Tumor necrosis factor inhibitor labeling should carry class warnings for the risks of lymphoma and congestive heart failure, FDA's Arthritis Advisory Committee recommended March 4
You may also be interested in...
Centocor Remicade "Dear Doctor" Letter Warns Against Use In CHF
Centocor will revise Remicade labeling to warn against use in congestive heart failure after the company completes analysis of Phase II results showing an adverse impact from infliximab.
Enbrel, Remicade Anti-TNF Class Labeling Debated By FDA Advisory Cmte.
Anti-TNF rheumatoid arthritis drug class labeling for tuberculosis risk was discussed by FDA's Arthritis Advisory Committee during an Aug. 17 safety update on Immunex' Enbrel (etanercept) and Centocor's Remicade (infliximab).
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011